Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness

Manuel Neves, Fernanda Trigo, Bergantim Rui, Cristina João, Paulo Lúcio, Neves Mariana, João Mendes, Hugo Pedrosa () and Catarina Geraldes
Additional contact information
Manuel Neves: Clinical Center of the Champalimaud Center for the Unknown
Fernanda Trigo: Centro Hospitalar S. João
Bergantim Rui: Centro Hospitalar S. João
Cristina João: Clinical Center of the Champalimaud Center for the Unknown
Paulo Lúcio: Clinical Center of the Champalimaud Center for the Unknown
Neves Mariana: IQVIA Solutions Portugal
João Mendes: Janssen Portugal
Hugo Pedrosa: IQVIA Solutions Portugal
Catarina Geraldes: Centro Hospitalar e Universitário de Coimbra

PharmacoEconomics, 2021, vol. 39, issue 5, No 8, 579-587

Abstract: Abstract Background Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific economic data at the country level remain scarce. Objective This study assesses the burden and cost of MM in Portugal from the perspective of the National Health Service (NHS) to support the definition of health policies, resource allocation and patient care. Methods Developed by the Portuguese Multiple Myeloma Group, this study considers the most recent available data. Burden of disease was measured using disability-adjusted life-years (DALYs). The cost of MM was estimated using a prevalence-based model that estimated direct costs for the NHS considering all costs associated with diagnosis, hospitalizations, surgeries, emergency visits, medical appointments, drugs and transportation. Costs were quantified based on the diagnosis-related group funding price, except for drug usage, which was calculated using the average hospital product stock price. Results The burden of disease attributable to MM for 2018 was estimated at 8931 DALYs: 8570 resulting from premature deaths and 361 from disability. Average yearly direct costs per patients with MM amounted to €31,449 (year 2018 values). Total direct costs are estimated at €61 million per year. Conclusions The mortality rate in MM means that most DALYs are due to years of life lost rather than years lost due to disability. This study generates comprehensive data on the burden and cost of MM in Portugal and provides updated insights into the costs associated with the management of MM.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00993-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-020-00993-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00993-5

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().